Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, today announced its participation in the upcoming Informa Life Sciences 3rd Annual Antibody-Drug Conjugates Conference.

Dr. Timothy B. Lowinger, Chief Scientific Officer, is scheduled to present, “Next-generation ADCs: Enabling alternative payloads and alternative targeting agents” on Wednesday, June 12, 2013, at 5:30 p.m. at the Hotel Fira Palace in Barcelona, Spain.

About Mersana

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Utilizing its proprietary conjugation technology, which is comprised of the Fleximer® polymer and a broad array of customizable linker chemistries, Mersana is developing its next-generation antibody-drug conjugate (ADC) platform with superior properties not found with other ADC technologies. Mersana is currently working with a number of top Pharma companies to develop next generation Fleximer-ADCs and most recently announced a $270 million collaboration with Endo Pharmaceuticals in March, 2012. The company is also advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. 

Media Contact

 MacDougall Biomedical Communications
 Kari Watson
 781-235-3060
 kwatson@macbiocom.com